title: Differential susceptibility of HLA class II antigens induced by gamma-interferon in human neuroblastoma cell lines.
abstract: Five neuroblastoma cell lines have been examined for the induction of HLA class II antigens by a recombinant gamma-interferon. The expression of HLA-DR and -DP was induced on up to 80% of cells in two of five neuroblastoma cell lines examined (KP-N-SI and KP-N-RT). Low expression of HLA-DR and -DP was induced on the SK-N-DZ line in the presence of recombinant gamma-interferon for 10 days. In contrast HLA-DQ was not induced on any of five neuroblastoma cell lines studied. HLA-DR and -DP antigen induction was reversible, falling to nondetectable levels when interferon was removed from the culture medium. The reinduction of interferon to the culture medium again induced HLA-DR and -DP antigen expression in a fashion similar to that originally observed. These results were confirmed by Northern blot analysis using a probe to HLA-DR alpha mRNA. Recombinant interferon appears to induce HLA class II expression at the level of gene transcription or posttranscription. The results also indicate that HLA-DR, -DP, and -DQ antigens are independently regulated. Treatment of neuroblastoma cell lines with gamma-interferon results in the induction of a differentiated phenotype. Although the cytokine gamma-interferon induces neurofilament expression in some of the cell lines, this was not the case for all lines studied. Thus no correlation could be established between the morphological differentiation and either HLA class II or neurofilament expression. In addition, no correlation between response to recombinant interferon and N-myc amplification was noted. The biological significance of HLA class II expression on neuroblastoma cell lines by gamma-interferon may be related to the differentiation stage of neuroblastoma cells or may enable gamma-interferon-treated neuroblastoma cells to be recognized by cytotoxic T-cells.
authors.affiliation: Children's Research Hospital, Department of Pediatrics, Kyoto Prefectural University of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Horii
authors.forename: T
authors.initials: T
authors.lastname: Hino
authors.forename: J T
authors.initials: JT
authors.lastname: Kemshead
authors.forename: H
authors.initials: H
authors.lastname: Kuroda
authors.forename: T
authors.initials: T
authors.lastname: Sawada
authors.forename: H
authors.initials: H
authors.lastname: Morioka
authors.forename: J
authors.initials: J
authors.lastname: Imanishi
authors.forename: H
authors.initials: H
authors.lastname: Inoko
mesh_terms: D004305:Dose-Response Relationship, Drug; D005802:Genes, MHC Class II; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D007382:Intermediate Filaments; D007700:Kinetics; D009447:Neuroblastoma / Q000276:immunology* / Q000473:pathology / Q000648:ultrastructure; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured
chemical_list: D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D011994:Recombinant Proteins; D007371:Interferon-gamma